Joseph Wender Biography and Net Worth

Director of Ionis Pharmaceuticals

Mr. Wender has served as a director of Ionis since January 1994. Mr. Wender began with Goldman, Sachs & Co. in 1971 and became a general partner of that firm in 1982, where he headed the Financial Institutions Group for over a decade. Since January 2008, he has been a senior consultant to Goldman Sachs & Co. He is also an Independent Trustee of the Schwab Family of Funds and Director of Grandpoint Capital, a bank holding company. Mr. Wender also is co-CEO and minority partner, with his wife, of Colgin Cellars. Since March 2014, Mr. Wender has been a director, and is currently lead director, of Outfront Media, lessors of advertising space on out-of-home advertising structures.

What is Joseph H. Wender's net worth?: The estimated net worth of Joseph H. Wender is at least $2.95 million as of December 1st, 2025. Mr. Wender owns 36,035 shares of Ionis Pharmaceuticals stock worth more than $2,948,023 as of December 5th. This net worth evaluation does not reflect any other investments that Mr. Wender may own. Learn More about Joseph H. Wender's net worth.
How do I contact Joseph H. Wender?: The corporate mailing address for Mr. Wender and other Ionis Pharmaceuticals executives is 2855 GAZELLE COURT, CARLSBAD CA, 92010. Ionis Pharmaceuticals can also be reached via phone at (760) 931-9200 and via email at [email protected]. Learn More on Joseph H. Wender's contact information.
Has Joseph H. Wender been buying or selling shares of Ionis Pharmaceuticals?: Within the last three months, Joseph H. Wender has sold $5,435,920.00 of Ionis Pharmaceuticals stock. Most recently, Joseph H. Wender sold 28,000 shares of the business's stock in a transaction on Monday, December 1st. The shares were sold at an average price of $80.82, for a transaction totalling $2,262,960.00. Following the completion of the sale, the director now directly owns 36,035 shares of the company's stock, valued at $2,912,348.70. Learn More on Joseph H. Wender's trading history.
Who are Ionis Pharmaceuticals' active insiders?: Ionis Pharmaceuticals' insider roster includes Joseph Baroldi (EVP & Chief Business Officer), C. Bennett (EVP), Spencer Berthelsen (Director), Brian Birchler (EVP), Onaiza Cadoret-Manier (EVP), Breaux Castleman (Director), Stanley Crooke (Chairman), Shannon Devers (Executive Vice President, Chief Human Resources Officer), Allene Diaz (Director), Richard Geary (EVP), Michael Hayden (Director), Elizabeth Hougen (CFO), Joseph Klein, III (Director), Brett Monia (CEO), Frederick Muto (Director), Patrick O'Neil (EVP), B. Parshall, Esq. (Director), Eugene Schneider (EVP), Eric Swayze (EVP), and Joseph Wender (Director). Learn More on Ionis Pharmaceuticals' active insiders.
Are insiders buying or selling shares of Ionis Pharmaceuticals?: During the last year, Ionis Pharmaceuticals insiders bought shares 2 times. They purchased a total of 20,000 shares worth more than $659,000.00. During the last year, insiders at the sold shares 59 times. They sold a total of 1,110,343 shares worth more than $67,968,421.56. The most recent insider tranaction occured on December, 1st when Director Joseph H Wender sold 28,000 shares worth more than $2,262,960.00. Insiders at Ionis Pharmaceuticals own 2.6% of the company. Learn More about insider trades at Ionis Pharmaceuticals.
Information on this page was last updated on 12/1/2025.

Joseph H. Wender Insider Trading History at Ionis Pharmaceuticals

Transaction Date	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Shares Held After Transaction
12/1/2025	Sell	28,000	$80.82	$2,262,960.00	36,035
10/31/2025	Sell	11,200	$75.16	$841,792.00	64,035
10/30/2025	Sell	16,800	$73.26	$1,230,768.00	75,235
10/1/2025	Sell	16,800	$65.50	$1,100,400.00	92,035
9/3/2025	Sell	11,200	$60.14	$673,568.00	108,835
9/2/2025	Sell	16,800	$55.87	$938,616.00	120,035
3/19/2019	Sell	10,000	$79.63	$796,300.00
5/11/2018	Sell	15,000	$45.31	$679,650.00	36,649
3/2/2015	Sell	7,000	$65.97	$461,790.00
6/20/2013	Sell	5,447	$20.93	$114,005.71

Joseph H. Wender Buying and Selling Activity at Ionis Pharmaceuticals

Ionis Pharmaceuticals Company Overview

Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy. It also develops medicines for various indications that are in phase 3 study, including Eplontersen as a monthly self-administered subcutaneous injection to treat all types of ATTR; Olezarsen for patients with FCS and severe hypertriglyceridemia (SHTG); Donidalorsen for patients with hereditary angioedema; ION363 for patients with amyotrophic lateral sclerosis; Tofersen to inhibit the production of superoxide dismutase 1; Pelacarsen for patients with established cardiovascular disease and elevated lipoprotein(a); and Bepirovirsen to inhibit the production of viral proteins associated with hepatitis B virus. In addition, the company develops IONIS-FB-LRx to inhibit the production of complement factor B and the alternative complement pathway; and ION224 to reduce the production of diacylglycerol acyltransferase 2. It has a strategic collaboration with Biogen for the treatment of neurological disorders; and collaboration and license agreement with Metagenomi, Inc, AstraZeneca, Bayer AG, GlaxoSmithKline plc, Novartis, Roche, Swedish Orphan Biovitrum AB, and PTC Therapeutics. The company was incorporated in 1989 and is based in Carlsbad, California.

Today's Range

Now: $81.81

$81.45

$83.61

50 Day Range

MA: $73.24

$64.09

$82.75

2 Week Range

Now: $81.81

$23.95

$83.61

Volume

2,317,797 shs

Average Volume

3,112,748 shs

Market Capitalization

$13.25 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.3